Lilly and Schrödinger Ink $425 Million Small Molecule Partnership

Published on: 
In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter, November 2022, Volume 17, Issue 11

Eli Lilly and Company will partner with Schrödinger to develop and optimize small molecule compounds.

Schrödinger, a pharmaceutical company that utilizes a specialized computational platform for drug discovery, announced a collaboration with Eli Lilly and Company (Lilly) on Oct. 6, 2022. The collaboration is focused on discovering and optimizing small molecule compounds for a designated target.

According to a company press release, Schrödinger will be responsible for the discovery and optimization process, while Lilly will handle completion of preclinical development, clinical development, and commercialization. Schrödinger will receive an upfront payment and be eligible to receive up to $425 million, contingent on various discovery, development, and commercial milestone payments. Schrödinger will also be eligible to receive low single - to low double-digit royalties on net sales of any products emerging from the collaboration.

Source: Schrödinger